Development of an injectable formulation for the novel lipid A analog E5531 using a 'pH-jump method'.
In order to design an injectable formulation of E5531, a novel synthetic disaccharide analog of novel lipid A, for the treatment of septic shock, a 'pH-jump method' was developed. In this method, E5531 was dispersed in 0.003 mol/l NaOH (pH 11.0, above pK(a2)) at 50 degrees C (above phase transition temperature) and then mixed with a buffer to neutralize the pH to 7.3. E5531 was dispersed as particles, and the size was approximately 20 nm. The structure of the particles was vesicular. After dispersal, the solution was sterilized using a filter, filled aseptically into vials, and lyophilized. The size of the particles did not change before and after lyophilization. The relationship between the physicochemical properties of the particles and the pharmacokinetics in rats after intravenous administration was investigated. The membrane fluidity of the particles was affected by the dispersal methods, the dispersal time in 0.003 mol/l NaOH in the pH-jump method, and the addition of Ca(2+) to the solution. The membrane fluidity was correlated with the pharmacokinetics in rats.
Asai
Yasuyuki
Y
Formulation Research Laboratory, Kawashima, Eisai Co., Ltd., Gifu 510-6195, Japan
D000818:Animals; D002118:Calcium; D002413:Cations, Divalent; D055598:Chemical Phenomena; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D002627:Chemistry, Physical; D006863:Hydrogen-Ion Concentration; D007267:Injections; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008560:Membrane Fluidity; D010316:Particle Size; D051381:Rats
D002413:Cations, Divalent; D008050:Lipid A; C092845:E 5531; D002118:Calcium